Illumina, Inc. vs Global X Lithium & Battery Tech ETF — how do they compare? Illumina, Inc. trades at $189.78 (market cap $27.94B), while Global X Lithium & Battery Tech ETF trades at $69.25. The key difference: Illumina, Inc. is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | LIT | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $194.33 | $91.62 |
52-Week Low | $91.00 | $40.80 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
LIT trades at $66.92, down 2.14% on the day, reflecting recent volatility amid shifting EV market dynamics. The ETF has doubled over the past year, driven by strong momentum in lithium, energy storage, and semiconductor sectors. Key holdings benefit from global EV sales growth, with June marking the fourth consecutive monthly increase. A dividend of $0.32 is scheduled for July 2026, providing income potential.
Outlook remains positive due to structural demand for lithium in EVs and renewables, though risks include Chinese export controls and U.S.-China trade tensions. Analyst sentiment is bullish, citing inflection in lithium markets and reshoring trends. Investors should monitor policy developments and supply chain stability for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →